KR102753593B1 - 5,10-메틸렌-(6r)-테트라하이드로폴산 및 디카르복시산을 포함하는 안정한 동결건조물 - Google Patents

5,10-메틸렌-(6r)-테트라하이드로폴산 및 디카르복시산을 포함하는 안정한 동결건조물 Download PDF

Info

Publication number
KR102753593B1
KR102753593B1 KR1020207007389A KR20207007389A KR102753593B1 KR 102753593 B1 KR102753593 B1 KR 102753593B1 KR 1020207007389 A KR1020207007389 A KR 1020207007389A KR 20207007389 A KR20207007389 A KR 20207007389A KR 102753593 B1 KR102753593 B1 KR 102753593B1
Authority
KR
South Korea
Prior art keywords
acid
methylene
lyophilisate
pharmaceutically acceptable
tetrahydrofolic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207007389A
Other languages
English (en)
Korean (ko)
Other versions
KR20200041354A (ko
Inventor
루돌프 모저
피올라 그뢴
토마스 암만
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20200041354A publication Critical patent/KR20200041354A/ko
Application granted granted Critical
Publication of KR102753593B1 publication Critical patent/KR102753593B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/06Oxalic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207007389A 2017-08-16 2018-08-15 5,10-메틸렌-(6r)-테트라하이드로폴산 및 디카르복시산을 포함하는 안정한 동결건조물 Active KR102753593B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17186518.1 2017-08-16
EP17186518 2017-08-16
PCT/EP2018/072077 WO2019034673A1 (en) 2017-08-16 2018-08-15 STABLE LYOPHILISATES COMPRISING 5,10-METHYLENE- (6R) -TETRAHYDROFOLIC ACID AND DICARBOXYLIC ACID

Publications (2)

Publication Number Publication Date
KR20200041354A KR20200041354A (ko) 2020-04-21
KR102753593B1 true KR102753593B1 (ko) 2025-01-10

Family

ID=59699495

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207007389A Active KR102753593B1 (ko) 2017-08-16 2018-08-15 5,10-메틸렌-(6r)-테트라하이드로폴산 및 디카르복시산을 포함하는 안정한 동결건조물

Country Status (10)

Country Link
US (1) US11337978B2 (enExample)
EP (1) EP3668516B1 (enExample)
JP (1) JP7232815B2 (enExample)
KR (1) KR102753593B1 (enExample)
CN (1) CN110996958B (enExample)
AU (1) AU2018317789B2 (enExample)
DK (1) DK3668516T3 (enExample)
ES (1) ES2902051T3 (enExample)
PT (1) PT3668516T (enExample)
WO (1) WO2019034673A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250319022A1 (en) 2022-06-08 2025-10-16 Merck Patent Gmbh Concentrated solutions comprising sodium 5,10-methylene-(6r)-tetrahydrofolate
EP4536186A1 (en) 2022-06-08 2025-04-16 Merck Patent GmbH Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid
EP4536188A1 (en) 2022-06-08 2025-04-16 Merck Patent GmbH Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid
AU2023282347A1 (en) * 2022-06-08 2025-01-16 Merck Patent Gmbh Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1215945A (en) 1983-03-20 1986-12-30 Bengt Gustavsson Fluid transfer system
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CH682664A5 (en) 1991-10-15 1993-10-29 Eprova Ag Stable salts of 5,10-methylene tetrahydrofolate.
CH684644A5 (de) 1992-07-13 1994-11-15 Eprova Ag 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
US20020103126A1 (en) 1997-04-18 2002-08-01 Roche Diagnostics Gmbh Stable pharmaceutical form of administration for peptides, proteins and nucleic acids
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
CH696628A5 (de) * 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
CH697021A5 (de) 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
CN101321518A (zh) * 2005-12-02 2008-12-10 阿德文特克斯药物有限公司 5,10-亚甲基四氢叶酸盐的稳定药物组合物
US20120252852A1 (en) 2011-03-29 2012-10-04 Sanofi Otamixaban formulations with improved stability
JP6235779B2 (ja) * 2012-03-28 2017-11-22 株式会社コーセー 葉酸含有組成物及び葉酸の安定化方法
EP2799061A1 (en) * 2013-04-30 2014-11-05 Aprofol AG Stable high dose pharmaceutical composition containing folates
EP2837631A1 (en) 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
CN107812195B (zh) 2014-09-04 2021-04-20 连云港金康和信药业有限公司 (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物
US10059710B2 (en) * 2016-02-17 2018-08-28 Merck & Cie Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid

Also Published As

Publication number Publication date
JP7232815B2 (ja) 2023-03-03
EP3668516B1 (en) 2021-09-22
WO2019034673A1 (en) 2019-02-21
RU2020110073A3 (enExample) 2022-01-24
US11337978B2 (en) 2022-05-24
CN110996958A (zh) 2020-04-10
ES2902051T3 (es) 2022-03-24
PT3668516T (pt) 2021-12-23
CN110996958B (zh) 2023-05-12
US20200368236A1 (en) 2020-11-26
CA3073127A1 (en) 2019-02-21
EP3668516A1 (en) 2020-06-24
KR20200041354A (ko) 2020-04-21
JP2020531415A (ja) 2020-11-05
DK3668516T3 (da) 2021-12-13
RU2020110073A (ru) 2021-09-16
AU2018317789B2 (en) 2023-06-29
AU2018317789A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
KR102753593B1 (ko) 5,10-메틸렌-(6r)-테트라하이드로폴산 및 디카르복시산을 포함하는 안정한 동결건조물
EP2291375B1 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
JP5891234B2 (ja) 1h−ピロロ[2,3−b]ピリジン誘導体
EP2670748B1 (de) 7-azaindolderivate
EP2155745B1 (de) 6-(Pyrrolopyridinyl)- Pyrimidin-2-yl-Amin-Derivate und ihre Verwendung zur Behandlung von Krebs und Aids
JP2009530321A (ja) 4−(ピロロピリジニル)ピリミジニル−2−アミン誘導体
CN101918404A (zh) 4-(吡咯并[2,3-c]吡啶-3-基)-嘧啶-2-胺衍生物
DE102010049877A1 (de) 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
EP2794602A1 (de) 3-cyanaryl-1h-pyrazolo-(2,3-b-)pyridinderivate
JP5847091B2 (ja) ピロロピリジニルピリミジン−2−イルアミン誘導体
EP2516442B1 (de) Pyrrolo[2,3-d]pyrazin-7-yl-Pyrimidin-Verbindungen
EP2646438A1 (de) 3-hetaryl-substituierte pyrrolo[2,3-b]pyridin-derivative als pdk1 - inhibitoren
JP2015531381A (ja) 腫瘍の処置のための7−アザインドール−2,7−ナフチリジン誘導体
DE102008025751A1 (de) 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
RU2796570C2 (ru) Стабильные лиофилизаты, содержащие 5,10-метилен-(6r)-тетрагидрофолиевую кислоту
HK40027655A (en) Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid and a dicarboxylic acid
HK40027655B (en) Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid and a dicarboxylic acid
EP2121682B1 (de) 4-(pyrrolopyridinyl)-pyrimidin-2-yl-amin-derivate
WO2017059401A2 (en) Androgen receptor ligands
HK1140203A (en) 4-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200312

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210811

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240220

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241126

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250108

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250108

End annual number: 3

Start annual number: 1

PG1601 Publication of registration